Peptide Based Hematological Disorders Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022

Published on : Aug-2017 | List of Tables : 140 | List of Figures : 42 | No. of Pages : 170 | Report Code : FACT189MR | Format : ppt pdf Excel Word

Due to the advances in technology, the manufacturers and suppliers are encouraged to seek novel methods for peptide manufacturing, which is bound to improve the production of longer and complex chain of peptides and reduce the cost of production. Moreover, due to the automation of instruments, with improvements in the purification process and reduction in the total waste generated, are the driving factors triggering the growth of the global peptide therapeutics market. However, the synthesis and purification of long peptides is challenging for the manufacturers. Also, the rise in modifications and the addition of more unnatural amino acids have further increased the complications in peptide synthesis. This makes the manufactures of peptides difficult, and therefore the gap between demand and supply is increasing. Also, the manufacturing of peptides is a costly process, which hampers the growth of the global peptide therapeutics market.

Haematological disorders are the disorders related to problems in blood and blood components such as red blood cells, white blood cells, platelets, blood vessels, lymph nodes, spleen, bone marrow and the problems related to the proteins involved in bleeding and clotting (haemostasis and thrombosis). Therapeutic peptides are used in the treatment of haematological disorders mentioned above. Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Such type of covalent chemical bonds are formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are differentiated from proteins on the basis of size, and peptides contain 50 amino acids or less approximately.  

This Fact.MR report on the global peptide based hematological disorders therapeutics market forecasts that the global peptide based hematological disorders therapeutics market will touch a value of nearly US$ 530 Mn in the year 2022 and grow at a robust CAGR during the assessment period.

Market Taxonomy

Drug

Distribution Channel

Icatibant

Hospital Pharmacies

Ecallantide

Retail Pharmacies

 

Online Pharmacies

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

North America Market Set to Dominate the Global Peptide Based Hematological Disorders Therapeutics Market in Terms of Revenue

The market in North America is set to dominate the global peptide based hematological disorders therapeutics market in terms of value and this trend is projected to sustain itself throughout the assessment period. North America peptide based hematological disorders therapeutics market is the most attractive market, growing at a robust CAGR over the assessment period.

Icatibant Segment Poised to Touch a Value of Nearly US$ 410 Mn in 2022

As per the forecast of Fact.MR, the icatibant segment is expected to reach a value of nearly US$ 410 Mn in the year 2022. This represents a robust CAGR during the forecast period of 2017-2022. Icatibant segment is expected to account for more than three-fourth of the revenue share of the drug segment by the year 2017 and is expected to lose market share by the end of the year 2022.  

Hospital Pharmacies Segment to exhibit a CAGR of 7.4% During the Assessment Period

As per the forecast of Fact.MR, the hospital pharmacies segment is slated to touch a figure of nearly US$ 260 Mn in the year 2022. This represents a CAGR of 7.4% during the assessment period from 2017 till the year 2022. This segment is expected to lose market share by the end of the year 2022. The hospital pharmacies segment is expected to account for more than half of the revenue share of the distribution channel segment by the year 2017.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of global peptide based hematological disorders therapeutics market through 2022, which includes Shire plc.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

Global peptide based hematological disorders therapeutics market is exhibiting robust growth. As the manufacturers are developing novel methods for the development of new peptides that are used in curing of hematological disorders with decreasing cost, this market is showing a positive trajectory. This Fact.MR report analyzes the expansion of global peptide based hematological disorders therapeutics market till date, and provides key insights on the growth of the market during the forecast period, 2017-2022.

Scope

The scope of Fact.MR’s report is to analyze the global peptide based hematological disorders therapeutics market for the forecast period 2017-2022 and provide readers an unbiased and accurate analysis. Peptide based hematological disorders therapeutics providers, research institutes and key players in the global peptide based hematological disorders market can benefit from the analysis offered in this report. This report offers a comprehensive analysis, which can be of interest to leading trade magazines and medical journals pertaining to peptide based hematological disorders therapeutics.

Summary

The report commences with a brief information of the global peptide based hematological disorders therapeutics market. This executive summary sets the tone for the rest of the report, providing users the scope of the report. The executive summary includes important facts and statistics on the global peptide based hematological disorders therapeutics market.

Overview

The next section offers an overview of the global peptide based hematological disorders therapeutics market. This comprises an introduction to the market, along with a standard definition of the service – peptide based hematological disorders therapeutics. In this section, market value and year-over-year growth is offered to the readers. Year-over-year growth provides readers with a broader view of growth patterns over the forecast period.

The report’s succeeding section focuses on drivers, restraints and key trends from macroeconomic, demand, and supply perspectives. Impact analysis of weighted average model-based growth drivers is contained in the report for better provision of decision-making insights to clients.

In order to offer readers with up-to-date information about the latest advancements in the global peptide based hematological disorders therapeutics market, the report provides updates about market opportunities, which can benefit leading service providers of peptide based hematological disorders therapeutics. With continuous evolution of the healthcare sector, keeping a record of latest developments and trends is fundamental for peptide based hematological disorders therapeutics market players to formulate key business strategies. Detailed insights about raw material sourcing, supply chain, regulatory approvals, pricing analysis, list of healthcare service providers, and cost structure are provided in this section.

The Fact.MR report provides segment-wise analysis and forecast for covering the wide scope of global peptide based hematological disorders therapeutics market. Drug type, distribution channel and region are key segments that define the growth of the global market for peptide based hematological disorders therapeutics. In this segmentation analysis, a detailed country-wise forecast across all key market parameters is also included.

The report’s last section comprises of the global peptide based hematological disorders therapeutics market competitive landscape, to provide readers with the dashboard view of company analysis and market players. This competitive intelligence is based on the providers’ categories across value chain, and their presence in the global peptide based hematological disorders therapeutics market.

Research Methodology

Fact.MR is committed to offer unbiased and independent market research solutions to its clients. Each market report of Fact.MR is compiled after months of exhaustive research. We bank on a mix of tried-and-tested and innovative research methodologies to offer the most comprehensive and accurate information. Our main sources of research include,

  • Primary research
  • Secondary research
  • Trade research
  • Focused interviews
  • Social media analysis

1. Global Peptide Based Hematological Disorders Therapeutics Market - Executive Summary

2. Global Peptide Based Hematological Disorders Therapeutics Market Overview
2.1. Introduction
       2.1.1. Global Peptide Based Hematological Disorders Therapeutics Market Taxonomy
       2.1.2. Global Peptide Based Hematological Disorders Therapeutics Market Definition
2.2. Global Peptide Based Hematological Disorders Therapeutics Market Size (US$ Mn) and Forecast, 2012-2022
       2.2.1. Global Peptide Based Hematological Disorders Therapeutics Market Y-o-Y Growth
2.3. Global Peptide Based Hematological Disorders Therapeutics Market Dynamics
2.4. Regulations
2.5. Supply Chain
2.6. Cost Structure
2.7. Average Pricing Analysis 
2.8. Epidemiology
2.9. Key Participants Market Presence (Intensity Map) By Region

3. Global Peptide Based Hematological Disorders Therapeutics Market Analysis and Forecast By Drug 
3.1. Global Peptide Based Hematological Disorders Therapeutics Market Size and Forecast By Drug, 2012-2022
       3.1.1. Icatibant Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                3.1.1.1. Revenue (US$ Mn) Comparison, By Region
                3.1.1.2. Market Share Comparison, By Region
                3.1.1.3. Y-o-Y growth Comparison, By Region
       3.1.2. Ecallantide Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                3.1.2.1. Revenue (US$ Mn) Comparison, By Region
                3.1.2.2. Market Share Comparison, By Region
                3.1.2.3. Y-o-Y growth Comparison, By Region

4. Global Peptide Based Hematological Disorders Therapeutics Market Analysis and Forecast By Distribution Channel 
4.1. Global Peptide Based Hematological Disorders Therapeutics Market Size and Forecast By Distribution Channel, 2012-2022
       4.1.1. Hospital Pharmacies Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                4.1.1.1. Revenue (US$ Mn) Comparison, By Region
                4.1.1.2. Market Share Comparison, By Region
                4.1.1.3. Y-o-Y growth Comparison, By Region
       4.1.2. Retail Pharmacies Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                4.1.2.1. Revenue (US$ Mn) Comparison, By Region
                4.1.2.2. Market Share Comparison, By Region
                4.1.2.3. Y-o-Y growth Comparison, By Region
       4.1.3. Online Pharmacies Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                4.1.3.1. Revenue (US$ Mn) Comparison, By Region
                4.1.3.2. Market Share Comparison, By Region
                4.1.3.3. Y-o-Y growth Comparison, By Region

5. Global Peptide Based Hematological Disorders Therapeutics Market Analysis and Forecast By Region
5.1. Global Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       5.1.1. North America Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                5.1.1.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.2. Latin America Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                5.1.2.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.3. Europe Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                5.1.3.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.4. Japan Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                5.1.4.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.5. APEJ Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                5.1.5.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.6. MEA Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                5.1.6.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

6. North America Peptide Based Hematological Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
6.1. US Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       6.1.1. Revenue (US$ Mn) Comparison, By Drug 
       6.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
6.2. Canada Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       6.2.1. Revenue (US$ Mn) Comparison, By Drug 
       6.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

7. Latin America Peptide Based Hematological Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
7.1. Brazil Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       7.1.1. Revenue (US$ Mn) Comparison, By Drug 
       7.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
7.2. Mexico Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       7.2.1. Revenue (US$ Mn) Comparison, By Drug 
       7.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
7.3. Argentina Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       7.3.1. Revenue (US$ Mn) Comparison, By Drug 
       7.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

8. Europe Peptide Based Hematological Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
8.1. Germany Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       8.1.1. Revenue (US$ Mn) Comparison, By Drug 
       8.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.2. UK Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       8.2.1. Revenue (US$ Mn) Comparison, By Drug 
       8.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.3. France Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       8.3.1. Revenue (US$ Mn) Comparison, By Drug 
       8.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.4. Spain Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       8.4.1. Revenue (US$ Mn) Comparison, By Drug 
       8.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.5. Italy Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       8.5.1. Revenue (US$ Mn) Comparison, By Drug 
       8.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.6. Nordic Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       8.6.1. Revenue (US$ Mn) Comparison, By Drug 
       8.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

9. Japan Peptide Based Hematological Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
9.1. Japan  Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       9.1.1. Revenue (US$ Mn) Comparison, By Drug 
       9.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

10. APEJ Peptide Based Hematological Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
10.1. China Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       10.1.1. Revenue (US$ Mn) Comparison, By Drug 
       10.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.2. India Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       10.2.1. Revenue (US$ Mn) Comparison, By Drug 
       10.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.3. Malaysia Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       10.3.1. Revenue (US$ Mn) Comparison, By Drug 
       10.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.4. Thailand Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       10.4.1. Revenue (US$ Mn) Comparison, By Drug 
       10.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.5. Singapore Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       10.5.1. Revenue (US$ Mn) Comparison, By Drug 
       10.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.6. Australia Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       10.6.1. Revenue (US$ Mn) Comparison, By Drug 
       10.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

11. MEA Peptide Based Hematological Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
11.1. GCC Countries Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       11.1.1. Revenue (US$ Mn) Comparison, By Drug 
       11.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
11.2. South Africa Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       11.2.1. Revenue (US$ Mn) Comparison, By Drug 
       11.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
11.3. Nigeria Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       11.3.1. Revenue (US$ Mn) Comparison, By Drug 
       11.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
11.4. Israel Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
       11.4.1. Revenue (US$ Mn) Comparison, By Drug 
       11.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

12. Global Peptide Based Hematological Disorders Therapeutics Market Competition Landscape and Company Profile
12.1. Company Share Analysis By Region
12.2. Shire plc
       12.2.1. Company Overview
       12.2.2. Peptide Based Hematological Disorders Therapeutics Market Drug list
       12.2.3. Peptide Based Hematological Disorders Therapeutics Market Drug Sales Data and Key Financials
       12.2.4. Key Developments
       12.2.5. SWOT Analysis

13. Research Methodology

14. Secondary and Primary Sources

15. Assumptions and Acronyms

16. Disclaimer

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Peptide Based Hematological Disorders Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022